Neuroendocrine Tumors

Cabozantinib, a Multitargeted TKI, Active in Advanced Neuroendocrine Tumors

Charles Bankhead

April 2017, Vol 8, No 2 - Neuroendocrine Tumors

San Francisco, CA—The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients who previously received sunitinib (Sutent) or everolimus (Afinitor), according to results from a phase 2 clinical trial, reported Jennifer A. Chan, MD, MPH, Clinical Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, Boston, MA, at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Long-Term Data Support Safety of Lanreotide in Advanced Neuroendocrine Tumors

Charles Bankhead

April 2017, Vol 8, No 2 - Neuroendocrine Tumors

San Francisco, CA—Pooled data from 2 randomized clinical trials and several open-label extension studies confirmed the safety and quality-of-life effects of long-term (>12 months) use of the somatostatin analog lanreotide (Somatulin Depot) for advanced neuroendocrine tumors (NETs), including functioning and nonfunctioning NETs, reported Alexandria T. Phan, MD, Medical Oncologist, University of New Mexico Cancer Center, Albuquerque, and colleagues, at a poster session at the 2017 Gastrointestinal (GI) Cancers Symposium. [ Read More ]